Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brent Fraser

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Oncology (Toronto, Ont.)|May 26, 2023
The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891-9895Maureen Trudeau, Brent Fraser
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|January 14, 2023
Access to novel drugs and therapeutics for children and youth: Eliciting citizens' values to inform public funding decisionsCindy L Gauvreau, Lisa Wight, Mathushan Subasri, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment ExerciseWei Fang Dai, Erica Craig, Brent Fraser, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working GroupWei Fang Dai, Vanessa Arciero, Erica Craig, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Oncology (Toronto, Ont.)|May 26, 2023
The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891-9895Maureen Trudeau, Brent Fraser
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|January 14, 2023
Access to novel drugs and therapeutics for children and youth: Eliciting citizens' values to inform public funding decisionsCindy L Gauvreau, Lisa Wight, Mathushan Subasri, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment ExerciseWei Fang Dai, Erica Craig, Brent Fraser, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working GroupWei Fang Dai, Vanessa Arciero, Erica Craig, et al.
Pageof 1